The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Part A: Percentage recovery from baseline in serum AGT
Timeframe: Up to Day 4
Part B: Percentage recovery from baseline in mean seated office SBP
Timeframe: At Day 4 and Day 7
Alnylam Clinical Trial Information Line